Biovaxys Technology CorpCanadian Securities Exchange:BIOVView on OTCQB
- LAST PRICE0.0650
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0600/ 191
- Ask / Lots0.0650/ 23
- Open / Previous Close0.0650 / 0.0650
- Day Range
- 52 Week Range
- Volume29,200
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BIOV |
|---|---|---|
| 01:33 ET | 29000 | 0.065 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Biovaxys Technology Corp | 17.0M | -2.2x | --- |
BioMark Diagnostics Inc | 18.6M | -10.9x | --- |
BetterLife Pharma Inc | 13.6M | -2.5x | --- |
Quantum BioPharma Ltd | 14.7M | -0.4x | --- |
Sirona Biochem Corp | 21.0M | -6.7x | --- |
Resverlogix Corp | 16.7M | -1.0x | --- |
Company Information
BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.
Contact Information
- Headquarters
- 146 Thirtieth Street, Suite 100TORONTO, ON, Canada M8W 3D4
- Phone
- 604-262-8835
- Fax
- 604-262-8835
Executives
- President, Chief Operating Officer
- Kenneth Kovan
- Chief Executive Officer, Chief Financial Officer, Director
- James Passin
- Director
- Craig Loverock
- Independent Director
- Anthony Dutton
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $17.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 262.1M |
Biovaxys Technology Corp does not pay a dividend. | |
Beta | 3.50 |
EPS | $-0.03 |
Book Value | $-0.02 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
